15/03/2006 - 11:01

WAIMR signs biotech deal with Proteomics International

15/03/2006 - 11:01

Bookmark

Save articles for future reference.

The Western Australian Institute for Medical Research (WAIMR) has signed a new management deal with Perth-based company Proteomics International.

WAIMR signs biotech deal with Proteomics International

The Western Australian Institute for Medical Research (WAIMR) has signed a new management deal with Perth-based company Proteomics International.

WAIMR Director Professor Peter Klinken said the agreement was likely to dramatically strengthen the local proteomics industry.
Proteomics is the study of all of the proteins of living systems, cells and tissues.
"Proteomics is an exciting new field of science and a growing industry that promises to speed-up drug discovery and development to tackle disease," he said.

"It can also identify biomarkers that act as indicators of disease, which can lead to the creation of simple blood tests, replacing more invasive procedures used to monitor health disorders."

The new deal will see Proteomics International operate and manage the new proteomics node of WAIMR's Lotterywest State Biomedical Facility.

 

THE FULL MEDIA RELEASE APPEARS BELOW.

March 15th, 2006

Media Statement

NEW DEAL JUMP-STARTS BIOTECH INDUSTRY NICHE

The Western Australian Institute for Medical Research (WAIMR) has signed a new management deal with Perth-based company Proteomics International.

WAIMR Director Professor Peter Klinken said the agreement was likely to dramatically strengthen the local proteomics industry.

"Proteomics is an exciting new field of science and a growing industry that promises to speed-up drug discovery and development to tackle disease," he said.

"It can also identify biomarkers that act as indicators of disease, which can lead to the creation of simple blood tests, replacing more invasive procedures used to monitor health disorders."

The new deal will see Proteomics International operate and manage the new proteomics node of WAIMR's Lotterywest State Biomedical Facility.

"Proteomics International is a world-leader in proteomics and this agreement ensures our new state-of-the-art research equipment will be utilised to maximum capacity," said Professor Klinken.

"This has the potential to benefit much of the industry, from researchers across the globe to international pharmaceutical companies, and fast-track their research initiatives with improved turnaround times.

"Proteomics is a burgeoning new industry that WA has the capacity to drive internationally - particularly by providing services to countries such as India and China."

Professor Klinken said the agreement represented another big step forward in the WA Government and local industry's commitment to position WA as a world leader in the medical and biotechnology sectors.

"We are making massive strides in creating WA as a global powerhouse in this area and this deal will further help to attract significant investment to the State," he said.
Proteomics is the study of all of the proteins of living systems, cells and tissues.
-ends-

 

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options